Atsushi Fukunaga

Dr. Atsushi Fukunaga

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2020 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
CWCuixue Wang
Cuixue Wang
JZJiedong Zhou
Jiedong Zhou
JWJinquan Wang
Jinquan Wang
SLShujing Li
Shujing Li
AFAtsushi Fukunaga
Atsushi Fukunaga
HTHai Tian
Hai Tian
Chronic obstructive pulmonary disease (COPD) is emphysema and/or chronic bronchitis characterised by long-term breathing problems and poor airflow. The prevalence of COPD has increased over the last decade and the drugs most commonly used to treat it, such as glucocorticoids and bronchodilators, have significant therapeutic effects; however, they also cause side effects, including infection and immunosuppression. Here we reviewed the pathogenesis and progression of COPD and elaborated on the effects and mechanisms of newly developed molecular targeted COPD therapeutic drugs. Among these new drugs, we focussed on thioredoxin (Trx). Trx effectively prevents the progression of COPD by regulating redox status and protease/anti-protease balance, blocking the NF-κB and MAPK signalling pathways, suppressing the activation and migration of inflammatory cells and the production of cytokines, inhibiting the synthesis and the activation of adhesion factors and growth factors, and controlling the cAMP-PKA and PI3K/Akt signalling pathways. The mechanism by which Trx affects COPD is different from glucocorticoid-based mechanisms which regulate the inflammatory reaction in association with suppressing immune responses. In addition, Trx also improves the insensitivity of COPD to steroids by inhibiting the production and internalisation of macrophage migration inhibitory factor (MIF). Taken together, these findings suggest that Trx may be the ideal drug for treating COPD.

7 December 2020 in Allergy
Verified
Journal Article
Open access
PDF file
EKEmek Kocatürk
Emek Kocatürk
ASAndaç Salman
Andaç Salman
ICIvan Chérrez-Ojeda
Ivan Chérrez-Ojeda
PCPaulo Ricardo Criado
Paulo Ricardo Criado
JPJonny Peter
Jonny Peter
MMMarcus Maurer
Marcus Maurer
Introduction: The COVID‐19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown.Aim: To understand how CU patients are affected by the COVID‐19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID‐19.Materials and Methods: Our cross‐sectional, international, questionnaire‐based, multicenter UCARE COVID‐CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences.Results: The COVID‐19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID‐19 patient care, which negatively impacted on the care of urticaria patients. The rate of face‐to‐face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID‐19, but COVID‐19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID‐19.Conclusions: The COVID‐19 pandemic brings major changes and challenges for CU patients and their physicians. The long‐term consequences of these changes, especially the increased use of remote consultations, require careful evaluation.

5 April 2017 in Clinical Autonomic Research
Verified
Journal Article
Closed access
PDF file
AFAtsushi Fukunaga
Atsushi Fukunaga
KWKen Washio
Ken Washio
MHMayumi Hatakeyama
Mayumi Hatakeyama
YOYoshiko Oda
Yoshiko Oda
KOKanako Ogura
Kanako Ogura
CNChikako Nishigori
Chikako Nishigori

27 April 2020 in Allergy
Verified
Journal Article
Open access
MMMarcus Maurer
Marcus Maurer
WAWerner Aberer
Werner Aberer
RARosana Agondi
Rosana Agondi
MAMona Al-Ahmad
Mona Al-Ahmad
MAMaryam Ali Al-Nesf
Maryam Ali Al-Nesf
ACAnthony Castaldo
Anthony Castaldo

15 September 2022 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
AFAtsushi Fukunaga
Atsushi Fukunaga
YOYoshiko Oda
Yoshiko Oda
SIShinya Imamura
Shinya Imamura
MMMayuko Mizuno
Mayuko Mizuno
TFTakeshi Fukumoto
Takeshi Fukumoto
KWKen Washio
Ken Washio

15 October 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MHMayumi Hatakeyama
Mayumi Hatakeyama
AFAtsushi Fukunaga
Atsushi Fukunaga
KWKen Washio
Ken Washio
KTKumiko Taguchi
Kumiko Taguchi
YOYoshiko Oda
Yoshiko Oda
CNChikako Nishigori
Chikako Nishigori
UV radiation, particularly UVB, is the major risk factor for the induction of skin cancer, and it induces skin inflammation and immunosuppression. Although reports documented that Langerhans cells (LCs) play various roles in photobiology, little is known about whether they contribute to UVB-induced cutaneous inflammation. Recently, the anti-inflammatory effect of apoptotic cells was noted. This study focuses on the roles of LCs and apoptotic cells in UVB-induced cutaneous inflammation. We show that LCs are essential for resolution of UVB-induced cutaneous inflammation. Administration of quinolyl-valyl-O-methylaspartyl-[2,6-difluophenoxy]-methyl ketone, a broad-spectrum caspase inhibitor with potent antiapoptotic properties, inhibited the formation of UVB-induced apoptotic cells and aggravated UVB-induced cutaneous inflammation in wild-type mice. In contrast, exacerbation of UVB-induced cutaneous inflammation following quinolyl-valyl-O-methylaspartyl-[2,6-difluophenoxy]-methyl ketone administration was not observed in LC-depleted mice. These results suggest that the interaction between LCs and apoptotic cells is critical for resolution of UVB-induced cutaneous inflammation. Interestingly, UVB-induced apoptotic keratinocytes were increased in LC-depleted mice. In addition, we revealed that UVB-induced apoptotic keratinocytes were phagocytosed by LCs ex vivo and that prolongation of UVB-induced cutaneous inflammation following treatment with Cytochalasin D, an inhibitor of phagocytosis, was partially attenuated in LC-depleted mice. Collectively, our findings demonstrate that the interaction between LCs and apoptotic cells, possibly via LC-mediated phagocytosis of apoptotic keratinocytes, has an essential anti-inflammatory role in the resolution of UVB-induced cutaneous inflammation.